Cebix raises $16M

San Diego-based Cebix has raised $16 million over the last 14 months, according to filings obtained by Xconomy. The company is developing a replacement therapy based on human proinsulin C-peptide for the treatment of Type 1 diabetic neuropathy. Article

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.